Skip to main content
Erschienen in: Surgery Today 7/2020

05.06.2019 | Review Article

Effects of surgery on the patient-reported outcomes of primary hyperparathyroidism patients with mild hypercalcemia without classic symptoms: a systematic review of the literature

verfasst von: Kiyomi Horiuchi, Yusaku Yoshida, Takahiro Okamoto

Erschienen in: Surgery Today | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To establish if parathyroidectomy is beneficial for patient-reported outcomes (PROs), including quality of life (QoL), of patients with mild hypercalcemia ( < 1.0 mg/dl above the upper limit of reference ranges) caused by primary hyperparathyroidism without classic symptoms (mild PHPT).

Methods

We conducted a systematic review of the literature. Prospective studies were selected if PROs were measured before and after surgery and if the subpopulation of mild PHPT was clearly defined. Selected studies were appraised for their designs, PRO measures, and potential biases, as well as findings. Effect sizes were estimated to evaluate the extent of the benefits, if possible.

Results

Four randomized controlled trials and six observational studies were included in this analysis. Seven studies used the SF-36 to measure QoL and the other three used different scales. Quantitative data on outcomes were provided in the four observational studies, but effect sizes could not be estimated. A placebo effect of surgery was discussed in five studies. Statistically significant improvements in PROs were observed in all studies, but the clinical importance of the changes was not discussed in detail.

Conclusions

The surgical treatment of mild PHPT may be associated with improved PROs, but the clinical significance of the changes is not yet confirmed.
Literatur
1.
Zurück zum Zitat Walker MD, Silverberg SJ. Parathyroidectomy in asymptomatic primary hyperparathyroidism: Improves “bones” but not “psychic moans.” J Clin Endocrinol Metab. 2007;92:1613–5.CrossRef Walker MD, Silverberg SJ. Parathyroidectomy in asymptomatic primary hyperparathyroidism: Improves “bones” but not “psychic moans.” J Clin Endocrinol Metab. 2007;92:1613–5.CrossRef
2.
Zurück zum Zitat Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122–9.CrossRef Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122–9.CrossRef
3.
Zurück zum Zitat Coe FL, Favus MJ. Does mild, asymptomatic hyperparathyroidism require surgery? N Engl J Med. 1980;302:224–5.CrossRef Coe FL, Favus MJ. Does mild, asymptomatic hyperparathyroidism require surgery? N Engl J Med. 1980;302:224–5.CrossRef
4.
Zurück zum Zitat Niederle B, Wemeau JL. Is surgery necessary for 'mild' or 'asymptomatic' hyperparathyroidism? Eur J Endocrinol. 2015;173:D13–D20.CrossRef Niederle B, Wemeau JL. Is surgery necessary for 'mild' or 'asymptomatic' hyperparathyroidism? Eur J Endocrinol. 2015;173:D13–D20.CrossRef
5.
Zurück zum Zitat Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ III, Wermers RA. Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone. 2015;73:1–7.CrossRef Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ III, Wermers RA. Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone. 2015;73:1–7.CrossRef
6.
Zurück zum Zitat Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3561–9.CrossRef Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3561–9.CrossRef
7.
Zurück zum Zitat Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3580–94.CrossRef Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3580–94.CrossRef
8.
Zurück zum Zitat Ospina NS, Maraka S, Rodriguez-Gutierrez R, Espinosa de Ycaza AE, Jasim S, Gionfriddo M, et al. Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int. 2016;27:3395–407.CrossRef Ospina NS, Maraka S, Rodriguez-Gutierrez R, Espinosa de Ycaza AE, Jasim S, Gionfriddo M, et al. Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int. 2016;27:3395–407.CrossRef
9.
Zurück zum Zitat U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes. 2006;4:79 doi:10.1186/1477-7525-4-79. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes. 2006;4:79 doi:10.1186/1477-7525-4-79.
10.
Zurück zum Zitat Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374:369–70.CrossRef Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374:369–70.CrossRef
11.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–122.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–122.CrossRef
12.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef
13.
Zurück zum Zitat Bilezikian J, Potts J, Fuleihan G, Kleerekoper M, Neer R, Peacok M, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21th century. J Clin Endocrinol Metab. 2002;87:5353–61.CrossRef Bilezikian J, Potts J, Fuleihan G, Kleerekoper M, Neer R, Peacok M, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21th century. J Clin Endocrinol Metab. 2002;87:5353–61.CrossRef
14.
Zurück zum Zitat Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge: Cambridge University Press; 2010.CrossRef Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge: Cambridge University Press; 2010.CrossRef
15.
Zurück zum Zitat Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. Endocr J. 1997;44:367–74.CrossRef Okamoto T, Gerstein HC, Obara T. Psychiatric symptoms, bone density and non-specific symptoms in patients with mild hypercalcemia due to primary hyperparathyroidism: a systematic overview of the literature. Endocr J. 1997;44:367–74.CrossRef
16.
Zurück zum Zitat Coker LH, Rorie K, Cantley L, Kirkland K, Stump D, Burbank N, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg. 2005;242:642–50.CrossRef Coker LH, Rorie K, Cantley L, Kirkland K, Stump D, Burbank N, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg. 2005;242:642–50.CrossRef
17.
Zurück zum Zitat Brito K, Edirimanne S, Eslick GD. The extent of improvement of health-related quality of life as assessed by the SF36 and Paseika scales after parathyroidectomy in patients with primary hyperparathyroidism–a systematic review and meta-analysis. Int J Surg. 2015;13:245–9.CrossRef Brito K, Edirimanne S, Eslick GD. The extent of improvement of health-related quality of life as assessed by the SF36 and Paseika scales after parathyroidectomy in patients with primary hyperparathyroidism–a systematic review and meta-analysis. Int J Surg. 2015;13:245–9.CrossRef
18.
Zurück zum Zitat Cheng SP, Lee JJ, Liu TP, Yang PS, Liu SC, Hsu YC, et al. Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Medicine. 2015;94:e931.CrossRef Cheng SP, Lee JJ, Liu TP, Yang PS, Liu SC, Hsu YC, et al. Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Medicine. 2015;94:e931.CrossRef
19.
Zurück zum Zitat Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415–22.CrossRef Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415–22.CrossRef
20.
Zurück zum Zitat Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687–92.CrossRef Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687–92.CrossRef
21.
Zurück zum Zitat Ambrogini E, Cetani F, Cianferotti L, Vignail E, Banti C, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114–211.CrossRef Ambrogini E, Cetani F, Cianferotti L, Vignail E, Banti C, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114–211.CrossRef
22.
Zurück zum Zitat Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery. 2009;146:1116–22.CrossRef Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery. 2009;146:1116–22.CrossRef
23.
Zurück zum Zitat Edwards ME, Rotramel A, Beyer T, Gaffud MJ, Djuricin G, Loviscek K, et al. Improvement in the health-related quality-of-life symptoms of hyperparathyroidism is durable on long-term follow-up. Surgery. 2006;140:655–64.CrossRef Edwards ME, Rotramel A, Beyer T, Gaffud MJ, Djuricin G, Loviscek K, et al. Improvement in the health-related quality-of-life symptoms of hyperparathyroidism is durable on long-term follow-up. Surgery. 2006;140:655–64.CrossRef
24.
Zurück zum Zitat Caillard C, Sebag F, Mathonnet M, Gibelin H, Brunaud L, Loudot C, et al. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery. 2007;141:153–60.CrossRef Caillard C, Sebag F, Mathonnet M, Gibelin H, Brunaud L, Loudot C, et al. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery. 2007;141:153–60.CrossRef
25.
Zurück zum Zitat Blanchard C, Mathonnet M, Sebag F, Caillard C, Kubis C, Drui D, et al. Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann Surg Oncol. 2014;21:3534–40.CrossRef Blanchard C, Mathonnet M, Sebag F, Caillard C, Kubis C, Drui D, et al. Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann Surg Oncol. 2014;21:3534–40.CrossRef
26.
Zurück zum Zitat Ryhänen EM, Heiskanen I, Sintonen H, Välimäki MJ, Roine RP, Schalin-Jäntti C. Health-related quality of life is impaired in primary hyperparathyroidism and significantly improves after surgery: a prospective study using the 15D instrument. Endocr Connect. 2015;4:179-86.Zanocco K, Butt Z, Kaltman D, Elaraj D, Cella D, Holl JL, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158:837-45. Ryhänen EM, Heiskanen I, Sintonen H, Välimäki MJ, Roine RP, Schalin-Jäntti C. Health-related quality of life is impaired in primary hyperparathyroidism and significantly improves after surgery: a prospective study using the 15D instrument. Endocr Connect. 2015;4:179-86.Zanocco K, Butt Z, Kaltman D, Elaraj D, Cella D, Holl JL, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158:837-45.
27.
Zurück zum Zitat Zanocco K, Butt Z, Kaltman D, Elaraj D, Cella D, Holl JL, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158:837–45.CrossRef Zanocco K, Butt Z, Kaltman D, Elaraj D, Cella D, Holl JL, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158:837–45.CrossRef
28.
Zurück zum Zitat Bannani S, Christou N, Guérin C, Hamy A, Sebag F, Mathonnet M, et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg. 2018;105:223–9.CrossRef Bannani S, Christou N, Guérin C, Hamy A, Sebag F, Mathonnet M, et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg. 2018;105:223–9.CrossRef
29.
Zurück zum Zitat Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-15. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-15.
30.
Zurück zum Zitat Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, and the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-83. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, and the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-83.
31.
Zurück zum Zitat Streiner DL, Norman GR, Cairney J. Health Measurement Scales: A practical guide to their development and use. 5th Ed, Oxford University Press, 2015, p 268-9. Streiner DL, Norman GR, Cairney J. Health Measurement Scales: A practical guide to their development and use. 5th Ed, Oxford University Press, 2015, p 268-9.
32.
Zurück zum Zitat Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39:1039–47.CrossRef Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care. 2001;39:1039–47.CrossRef
33.
Zurück zum Zitat Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.PubMed Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.PubMed
34.
Zurück zum Zitat Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–54.CrossRef Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–54.CrossRef
35.
Zurück zum Zitat Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-8; discussion 518-9. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-8; discussion 518-9.
36.
Zurück zum Zitat Pasieka JL, Parsons LL, Demeure MJ, Wilson S, Malycha P, Jones J, et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002;26:942–9.CrossRef Pasieka JL, Parsons LL, Demeure MJ, Wilson S, Malycha P, Jones J, et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002;26:942–9.CrossRef
38.
Zurück zum Zitat Webb SM, Puig-Domingo M, Villabona C, Muñoz-Torres M, Marazuela M, Fernández D, et al. Validation of PHPQoL, a disease-specific quality-of-life questionnaire for patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2016;101:1571–8.CrossRef Webb SM, Puig-Domingo M, Villabona C, Muñoz-Torres M, Marazuela M, Fernández D, et al. Validation of PHPQoL, a disease-specific quality-of-life questionnaire for patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2016;101:1571–8.CrossRef
39.
Zurück zum Zitat Joborn C, Hetta J, Lind L, Rastad J, Akerström G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery. 1989;105:72–8.PubMed Joborn C, Hetta J, Lind L, Rastad J, Akerström G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery. 1989;105:72–8.PubMed
40.
41.
Zurück zum Zitat Stirrat GM, Farndon J, Farrow SC, Dwyer N. The challenge of evaluating surgical procedures. Ann R Coll Surg Engl. 1992;74:80–4.PubMedPubMedCentral Stirrat GM, Farndon J, Farrow SC, Dwyer N. The challenge of evaluating surgical procedures. Ann R Coll Surg Engl. 1992;74:80–4.PubMedPubMedCentral
42.
Zurück zum Zitat Fish RG, Crymes TP, Lovell M. Internal-mammary-artery ligation for angina pectoris: its failure to produce relief. N Engl J Med. 1958;259:418–20.CrossRef Fish RG, Crymes TP, Lovell M. Internal-mammary-artery ligation for angina pectoris: its failure to produce relief. N Engl J Med. 1958;259:418–20.CrossRef
43.
Zurück zum Zitat Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA. An evaluation of internalmammary-artery ligation by a double-blind technic. N Engl J Med. 1959;260:1115–8.CrossRef Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA. An evaluation of internalmammary-artery ligation by a double-blind technic. N Engl J Med. 1959;260:1115–8.CrossRef
44.
Zurück zum Zitat Vergnes JN, Marchal-Sixou C, Nabet C, Maret D, Hamel O. Ethics in systematic reviews. J Med Ethics. 2010;36:771–4.CrossRef Vergnes JN, Marchal-Sixou C, Nabet C, Maret D, Hamel O. Ethics in systematic reviews. J Med Ethics. 2010;36:771–4.CrossRef
Metadaten
Titel
Effects of surgery on the patient-reported outcomes of primary hyperparathyroidism patients with mild hypercalcemia without classic symptoms: a systematic review of the literature
verfasst von
Kiyomi Horiuchi
Yusaku Yoshida
Takahiro Okamoto
Publikationsdatum
05.06.2019
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 7/2020
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-019-01830-9

Weitere Artikel der Ausgabe 7/2020

Surgery Today 7/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.